- Kelun Pharma has reported a net income of 1.03 billion yuan for the first quarter.
- The Pharmaceutical company’s revenue sums up to 6.22 billion yuan for the same period.
- The firm garners impressive market confidence with 13 buys and 2 holds based on investment ratings.
- There are no sells reported for the given period, suggesting investor optimism toward Kelun Pharma.
A look at Sichuan Kelun Pharmaceutical Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 3 | |
| Dividend | 4 | |
| Growth | 5 | |
| Resilience | 3 | |
| Momentum | 4 | |
| OVERALL SMART SCORE | 3.8 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Using Smartkarma Smart Scores, the long-term outlook for Sichuan Kelun Pharmaceutical looks promising. With a solid Growth score of 5, the company is expected to expand steadily in the future. Additionally, it boasts a high Dividend score of 4, indicating good potential for consistent dividend payouts. In terms of Momentum, Sichuan Kelun Pharmaceutical scores a respectable 4, showing positive market momentum. While its Value and Resilience scores are at 3, these factors still indicate decent financial standing and stability. Overall, Sichuan Kelun Pharmaceutical appears to be positioned well for sustained growth and performance.
### Sichuan Kelun Pharmaceutical Co., Ltd. manufactures pharmaceutical products, including a range of large infusion products, tablets, capsules, antibiotic injections, lyophilized powder for injection, and traditional Chinese medicine. With a strong focus on diversified product offerings, the company aims to cater to various medical needs and markets. ###
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
